Structured treatment interruptions in HIV infection: benefit or disappointment? (Q35917152)

11 August 2017

1 reference

title

Structured treatment interruptions in HIV infection: benefit or disappointment? (English)

1 reference

11 August 2017

Bernard Hirschel

1 reference

11 August 2017

Annette Oxenius

1 reference

11 August 2017

publication date

1 June 2003

1 reference

Expert Review of Anti-infective Therapy

11 August 2017

published in

1 reference

11 August 2017

1 reference

11 August 2017

1 reference

11 August 2017

page(s)

129-139

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Recovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma Viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Metabolic complications associated with antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

In vivo migration and function of transferred HIV-1-specific cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Transient High Levels of Viremia in Patients with Primary Human Immunodeficiency Virus Type 1 Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Cytotoxic-T-Cell Responses, Viral Load, and Disease Progression in Early Human Immunodeficiency Virus Type 1 Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Vigorous HIV-1-Specific CD4 + T Cell Responses Associated with Control of Viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Host determinants in HIV infection and disease. Part 1: cellular and humoral immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Time to hit HIV, early and hard.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

STI and beyond: the prospects of boosting anti-HIV immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

A controlled trial of zidovudine in primary human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Antibody responses to antigenic determinants of influenza virus hemagglutinin. II. Original antigenic sin: a bone marrow-derived lymphocyte memory phenomenon modulated by thymus-derived lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Disquisitions on Original Antigenic Sin. II. Proof in lower creatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Therapeutic dendritic-cell vaccine for simian AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Skewed maturation of memory HIV-specific CD8 T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Variable fate of virus-specific CD4(+) T cells during primary HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Control of HIV despite the Discontinuation of Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.129

21 January 2018

Identifiers

DOI

10.1586/14787210.1.1.129

1 reference

11 August 2017

1 reference